Résumé
Les inhibiteurs de l’aromatase ont optimisé le pronostic du cancer du sein chez la femme ménopausée. Ils exposent cependant à des troubles musculosquelettiques, à des manifestations douloureuses articulaires et musculaires qui peuvent conduire à des difficultés d’observance, voire à des arrêts thérapeutiques très problématiques, à un risque accru d’ostéoporose et de fractures à plus long terme qui doivent être bien connus et pris en compte dans la décision thérapeutique. Avec la prolongation de l’espérance de vie, la prévention des troubles musculosquelettiques iatrogènes ne doit pas être négligée dans la prise en charge au long cours de ces patientes
Abstract
The use of aromatase inhibitors in postmenopausal patients with breast cancer have modified the pronostic and may prove to be the agents of choice in this setting. However this treatment is associated with an increased rate of short-term symptoms: articulary and muscle pain and long-term symptoms: bone loss and fractures. The decision making process is driven by the existence of these complications. With the continuation of the life expectation, the prevention of the osseous iatrogenic complications must not be neglected in the care of these patients.
This is a preview of subscription content, log in via an institution to check access.
Références
Baum M, Budzar AU, Cuzick J, et al., ATAC Trialist’s Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131–2139
Brufsky A, Harker W, Beck J, et al. (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 7: 829–836
Coleman RE, ATAC Trialist’s Group (2006) Effect of anastrozole on bone mineral density: 5 years results from the Anastrozole, Tamoxifen, Alone or in Combination (ATAC trial). J Clin Oncol 24: 5S (abstract 511)
Coleman RE, Ranks LM, Girgis SI, et al. (2007) Skeletal effects of exemestane on-bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8: 119–127
Confavreux CB, Fontana A, Guastalla JP, et al. (2007) Estrogen-dependant increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 3: 346–352
Coombes RC, Emma H, Gibson L, et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with early breast cancer. N Engl J Med 350: 1081–1092
Donnellan PP, Douglas SL, Cameron DA, et al. (2001) Aromatase inhibitors and arthralgia. J Clin Oncol 19: 2767
Eastell R, Hannon RA, Cuzick J, et al. (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial. J Bone Miner Res 21: 1215–1223
Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52: 2594–2598
Gonelli S, Cadimi A, Caffarelli C, et al. (2007) Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40: 205–210
Gnant M, Jakesz R, Mlineritsch H, et al. (2005) Zoledronic acid inhibits cancer treatment induced bone loss in premenopausal patients with breast cancer who are receiving adjuvant endocrine treatment. Breast 14(suppl 1): S44
Goss PE, Ingle JN, Martino S, et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802
Goss PE, Ingle JN, Martino S, et al. (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in positive receptor breast cancer: updated findings from NCIC CTG MA-17. J Natl Cancer Instit 97: 1262–1271
Greenspan SL, Bhattacharya RK, Sereika SM, et al. (2006) Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Clin Endocrinol Metab 92: 131–136
Jakesz R, Jonat W, Gnant M, et al. (2005) Switching of postmenopausal women with endocrine — responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455–462
Lester JE, Gutcher SA, Ellis SP, et al. (2007) Monthly oral ibandronate prevents anastrozole-induced bone loss during adjuvant treatment for breast cancer. One year results from the ARIBON study. J Clin Oncol 25 (abstract 553)
Moralès L, Pans S, Paridaens R, et al. (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane associated tenosynovial changes on magnetic resonance imaging. Breast Canc Res Treat 104: 87–91
Morel B, Marotte H, Miossec P (2007) Will steroidal aromatase inhibitors induce rheumatoid arthritis? Ann Rheum Dis 66: 557–558
Perez EA, Josse RG, Pritchard KI, et al. (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA-17. J Clin Oncol 24: 3629–3635
Thurlimann BJ, Keshaviah A, Coates AS, et al. (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1-98 collaborative Group. N Engl J Med 353: 2747–2757
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Khalifa, P., Lesur, A. Les troubles musculosquelettiques des anti-aromatases. Oncologie 9 (Suppl 3), HS5–HS10 (2007). https://doi.org/10.1007/s10269-007-0745-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-007-0745-7